Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

5 Aug 2020

Abstract excerpt

Antibodies targeting the immune checkpoint axis have been approved by the FDA for the treatment of a broad range of malignancies [ 1 ]. NKTCL is an aggressive hematological malignancy derived from NK or T cells with ubiquitous Epstein–Barr virus (EBV) infection, and there is no standard therapeutic option established for patients with relapse/refractory (RR) NKTCL. Although clinical use of immune checkpoint...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32753688
DOI: 10.1038/s41375-020-1000-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphomaPMID 32753688Read ↗

Recurrent <i>PD-L1</i> Structural Rearrangements in Natural Killer/T Cell Lymphoma Patients with Complete Response to PD-1 Blockade TherapySemantic proximity Read ↗

Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivitySemantic proximity Read ↗

The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs.Semantic proximity Read ↗

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.Semantic proximity Read ↗

Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patientSemantic proximity Read ↗

Rapidly progressed Natural Killer/ T cell Lymphoma with hyperleukocytosis and NOTCH4 mutation but without Epstein-Barr virus infection:A case reportSemantic proximity Read ↗

Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression.Semantic proximity Read ↗

Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes.Semantic proximity Read ↗

Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Case-Illustrated Narrative ReviewSemantic proximity Read ↗

Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profilingSemantic proximity Read ↗

Unmasking PD-1 Resistance by Next-Generation SequencingSemantic proximity Read ↗

Recurrent Mutations in Refractory/Relapsed Diffuse Large B-Cell Lymphoma by Targeted Gene Sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.